Your browser doesn't support javascript.
loading
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Long, Georgina V; Atkinson, Victoria; Cebon, Jonathan S; Jameson, Michael B; Fitzharris, Bernie M; McNeil, Catriona M; Hill, Andrew G; Ribas, Antoni; Atkins, Michael B; Thompson, John A; Hwu, Wen-Jen; Hodi, F Stephen; Menzies, Alexander M; Guminski, Alexander D; Kefford, Richard; Kong, Benjamin Y; Tamjid, Babak; Srivastava, Archana; Lomax, Anna J; Islam, Mohammed; Shu, Xinxin; Ebbinghaus, Scot; Ibrahim, Nageatte; Carlino, Matteo S.
Afiliación
  • Long GV; Melanoma Institute Australia, University of Sydney, Mater Hospital, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia. Electronic address: georgina.long@sydney.edu.au.
  • Atkinson V; Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, QLD, Australia; University of Queensland, Brisbane, QLD, Australia.
  • Cebon JS; Olivia Newton-John Cancer Research Institute, Austin Health, School of Cancer Medicine, LaTrobe University, Heidelberg, VIC, Australia.
  • Jameson MB; Regional Cancer Centre, Waikato Hospital, Hamilton, New Zealand.
  • Fitzharris BM; Canterbury District Health Board, Christchurch Hospital, Christchurch, New Zealand.
  • McNeil CM; Royal Prince Alfred Hospital, Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Chris O'Brien Lifehouse, Camperdown, NSW, Australia.
  • Hill AG; Tasman Oncology Research, Southport Gold Coast, QLD, Australia.
  • Ribas A; Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Atkins MB; Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Thompson JA; Department of Medicine, University of Washington, Seattle, WA, USA.
  • Hwu WJ; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hodi FS; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Menzies AM; Melanoma Institute Australia, University of Sydney, Mater Hospital, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia.
  • Guminski AD; Melanoma Institute Australia, University of Sydney, Mater Hospital, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia.
  • Kefford R; Westmead Hospital, Melanoma Institute Australia, Macquarie University, Sydney, NSW, Australia.
  • Kong BY; Westmead Hospital, Westmead, NSW, Australia; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Blacktown Hospital, Blacktown, NSW, Australia.
  • Tamjid B; Olivia Newton-John Cancer Research Institute, Austin Health, School of Cancer Medicine, LaTrobe University, Heidelberg, VIC, Australia.
  • Srivastava A; Regional Cancer Centre, Waikato Hospital, Hamilton, New Zealand.
  • Lomax AJ; Royal Prince Alfred Hospital, Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Chris O'Brien Lifehouse, Camperdown, NSW, Australia.
  • Islam M; Tasman Oncology Research, Southport Gold Coast, QLD, Australia.
  • Shu X; Merck & Co, Kenilworth, NJ, USA.
  • Ebbinghaus S; Merck & Co, Kenilworth, NJ, USA.
  • Ibrahim N; Merck & Co, Kenilworth, NJ, USA.
  • Carlino MS; Westmead Hospital, Westmead, NSW, Australia; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Blacktown Hospital, Blacktown, NSW, Australia.
Lancet Oncol ; 18(9): 1202-1210, 2017 09.
Article en En | MEDLINE | ID: mdl-28729151
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Melanoma / Anticuerpos Monoclonales / Antineoplásicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte / Oceania Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Melanoma / Anticuerpos Monoclonales / Antineoplásicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte / Oceania Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article